207 related articles for article (PubMed ID: 33731665)
1. Primary BRAF Mutant Melanoma of the Lung Treated with Immunotherapy and Pulmonary Bilobectomy: A Case Report.
Bernal L; Restrepo J; Alarcón ML; Carvajal C; Bonilla CE; Ramírez AM; Beltrán R
Am J Case Rep; 2021 Mar; 22():e927757. PubMed ID: 33731665
[TBL] [Abstract][Full Text] [Related]
2. Primary endobronchial melanoma: a case report and clinical management indications.
Barisione E; Boutros A; Mora M; Spagnolo F; Tanda ET; Genova C; Tagliabue E
BMC Pulm Med; 2024 Feb; 24(1):97. PubMed ID: 38402179
[TBL] [Abstract][Full Text] [Related]
3. Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment.
Saleh M; Javadi S; Elsherif S; Patnana M; Sagebiel TL; Torres-Cabala C; Mattei J; Bhosale P; Faria SC
Radiographics; 2021; 41(7):1954-1972. PubMed ID: 34678102
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous toxicities of new treatments for melanoma.
Boada A; Carrera C; Segura S; Collgros H; Pasquali P; Bodet D; Puig S; Malvehy J
Clin Transl Oncol; 2018 Nov; 20(11):1373-1384. PubMed ID: 29799097
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
8. Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR; Mehnert JM
Cancer Treat Res; 2016; 167():295-320. PubMed ID: 26601869
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
11. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Melanoma.
Glitza Oliva IC; Alqusairi R
Adv Exp Med Biol; 2018; 995():43-63. PubMed ID: 30539505
[TBL] [Abstract][Full Text] [Related]
13. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
15. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
Chapman PB; Hauschild A; Sondak VK
Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
[TBL] [Abstract][Full Text] [Related]
16. PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach.
Proietti I; Filippi L; Michelini S; Porta N; Bernardini N; Mambrin A; Tolino E; Pacini L; Rosa P; Calogero A; Romeo G; Di Cristofano C; Petrozza V; Bagni O; Skroza N; Potenza C
Clin Ter; 2020; 171(4):e283-e287. PubMed ID: 32614358
[TBL] [Abstract][Full Text] [Related]
17. The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report.
Røe OD; Wahl SG
J Med Case Rep; 2017 Mar; 11(1):82. PubMed ID: 28343447
[TBL] [Abstract][Full Text] [Related]
18. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
19. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
20. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
